Physician profile
Mark Schamblin
NPI 1083645360
$13,503.88
in general payments reported to CMS, 2019-2025
13 companies · $56.86 in 2025
The $56.86 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,750 · 2020: $312 · 2021: $95.53 · 2022: $3,635 · 2023: $403 · 2024: $250 · 2025: $56.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $9,109.35 | 2019-2024 | Arthrex, Shoulder Implants Fibertak Knotless |
| Micromed INC | $1,778.82 | 2019-2022 | |
| Stryker Corporation | $1,604.27 | 2020-2024 | Aequalis Perform, Blueprint Patient Specific Instrumentation |
| Bioventus LLC | $362.05 | 2019-2020 | |
| Shoulder Innovations, INC. | $140.44 | 2023-2025 | Inset System |
| Abbott Laboratories | $116.94 | 2023-2024 | Gallant, Assurity |
| Nevro Corp. | $109.12 | 2021-2022 | |
| Zimmer Biomet Holdings, INC. | $98.83 | 2022 | |
| Vericel Corporation | $95.07 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.35 | 2022 | |
| Nalu Medical, INC. | $23.89 | 2024 | Nalu Neurostimulation System |
| Sanofi-Aventis U.S. LLC | $18.54 | 2019 | |
| Baudax Bio INC. | $18.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schamblin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.